Linked Life Data

16583786

Source:http://linkedlifedata.com/resource/pubmed/id/16583786

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-4-4
pubmed:abstractText
In late 2003, one manufacturer effected a fivefold increase in the price of its protease inhibitor (PI) ritonavir. Using the average wholesale price of each treatment regimen, IMS Health marketshare data, and epidemiologic data, the authors analyzed the effect of this price increase on the direct cost of ritonavir-boosted PI regimens. If 75% of individuals living with acquired immunodeficiency syndrome and 50% of those with human immunodeficiency virus infection in 2003 were receiving PI regimens, the total direct cost after the price rise was dollar 4 billion, an increase approaching dollar 1 billion. Moreover, the estimates of increased costs obtained in this study are assumed to be conservative.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
H
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1096-5645
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Effects of the ritonavir price increase on the cost of protease inhibitor regimens in United States.
pubmed:affiliation
Abt Associates, Bethesda, Maryland 20814-5341, USA. WonChan_Lee@abtassoc.com
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't